Cover Story: Sondii's Work Graces the Cover of a Cell Sub-journal! AI Breaks the Deadlock in Antibody–Drug Conjugate Development, Shifting from Trial‑and‑Error to Intelligent Precision.

《Volume 46, Issue 12》
Yuxi Wang^1,3,4, Cuiyu Guo^1,2,3,4 and Weimin Li^1,3

The cover of this issue of Trends in Pharmacological Sciences features Artificial intelligence in antibody–drug conjugate development by Professor Li Weimin and Researcher Wang Yuxi from West China Hospital.

Research Background

Antibody–drug conjugates (ADCs) hold great promise as a targeted cancer therapeutic modality, offering new hope for cancer treatment. By rationally combining antibodies, linkers, and payloads, ADCs are designed to achieve stability in systemic circulation and specific drug release at tumor sites, thereby precisely attacking cancer cells while minimizing damage to normal tissues. However, current ADC development faces multiple challenges. The design process is characterized by combinatorial complexity, requiring screening across numerous combinations of antibodies, linkers, and payloads; potential toxicity and adverse effects remain concerns; and clinical benefits vary considerably across different indications. Moreover, the development of effective ADCs necessitates rational matching of antibodies, linkers, and payloads—a process that is not only time‑consuming and costly but also predominantly relies on empirical trial‑and‑error approaches, which severely constrain the rapid advancement and broad application of ADCs.

Research Significance

The advent of artificial intelligence (AI) presents transformative opportunities for ADC development, driving a paradigm shift from empirical trial‑and‑error toward data‑driven closed‑loop engineering. AI models can integrate multimodal data, including sequences (for antibodies), structural features, and molecular dynamics (MD) simulations of ADC components. Leveraging these data, AI can play pivotal roles in multiple key aspects: accelerating target selection by rapidly identifying the most promising candidates from a vast pool of potential targets; optimizing conjugate design through simulation and analysis of various combinations to identify optimal antibody–linker–payload pairings; and predicting patient responses based on individual characteristics to enable personalized therapy. In these ways, AI substantially enhances the efficiency and success rate of ADC development, reduces costs, and offers more effective treatment options for cancer patients, thereby carrying profound implications for advancing targeted cancer therapy.

Research Outlook

In the preclinical stage, the sources and types of data fed into AI models can be further expanded to incorporate cellular‑level and animal‑model data, thereby improving the accuracy of predictions regarding ADC performance. Meanwhile, more advanced algorithms should be developed to better handle complex biological data and deepen our understanding of the intricate interactions among ADC components. In the clinical stage, AI can enable more precise patient stratification, tailoring the most suitable ADC regimens based on genomic profiles, tumor microenvironment characteristics, and other factors, thus enhancing the specificity and efficacy of clinical treatment. Furthermore, interdisciplinary collaboration—integrating AI with biotechnology, materials science, and other fields—should be strengthened to explore novel ADC architectures and mechanisms of action, ultimately giving rise to next‑generation AI‑empowered ADCs with higher efficacy and lower toxicity. Such efforts promise to bring about new breakthroughs in cancer therapy and improve both the survival and quality of life of cancer patients.

Cover Design Concept

The cover design aims to visually convey the core theme of "artificial intelligence in antibody–drug conjugate (ADC) development." The artwork presents a microscopic biomolecular scene in which antibodies, drug molecules, and cellular structures are interwoven, symbolizing the interactions among the key components of ADC development. By visualizing these microstructures, the design hints at the crucial role of artificial intelligence in deciphering and optimizing these complex biomolecular interactions, translating abstract scientific concepts into tangible visual forms.

The cover predominantly employs a dark color palette—deep purple and black serve as the background—creating a mysterious, profound, and professional scientific atmosphere that draws the reader into the microscopic biological world. In contrast, the molecular structures are rendered in a variety of bright, vividly contrasting colors, including blue, green, purple, and red. These vibrant hues not only make each molecular structure stand out against the dark background for enhanced visual clarity, but also symbolize the vitality and innovative spirit inherent in scientific research, while reflecting the convergence and interplay of diverse elements in ADC development.

The overall style of the cover is a high-tech, three‑dimensional realistic rendering. Through sophisticated 3D modeling techniques, the antibodies, drug molecules, and cellular structures are presented with a high degree of lifelike detail, offering strong stereoscopic and realistic effects. This style allows readers to intuitively appreciate the complexity and elegance of the microscopic world, embodies the rigor and precision of scientific inquiry, and adds to the visual appeal of the cover. Ultimately, the cover design received high recognition from both the supervising professor and the journal editors, and was successfully published as the cover image!